Patient P-02477
Synthetic patientMETA-24 · Day 113 · 45–54 · F · baseline S16Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
10%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S16
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability-4
- Nutritional resilience+3
- Toxicity-3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable81 min
worsening · -8.5 vs previous 14 d
Sleep duration
Wearable6.3 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log5.5/10
worsening · -1.2 vs previous 14 d
Steps
Wearable8,794
worsening · -917 vs previous 14 d
GI burden
Companion15.4/100
worsening · +18.0 vs previous 14 d
Adherence
Companion91.5 %
stable · +1.8 vs previous 14 d
Sleep quality
Wearable49.9/100
worsening · -7.5 vs previous 14 d
Glucose, CGM daily mean
CGM139 mg/dL
worsening · +6.4 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 75 from the failing basin, 25 from restoration.
Good elements to keep
- Protein (supports)perturbation · steering +12.8
- Butyrate producers intacthidden · steering +7.5
- Proteinsupporter · GI -6.2 next day
Main detractors to watch
- Bacteroides fragilis elevatedhidden · steering -7.4
- Alcoholperturbation · steering -6.4
- Low-HRV stretchperturbation · steering -2.7
- Alcohol on dosing daysperturbation · steering -1.8
- Alcoholdetractor · GI +4.4 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-6.2supporter · 95%
- Alcohol+4.4detractor · 79%
- Histamine load+1.2no signal · 17%
- Simple carbohydrates-0.8no signal · 15%
- Insoluble fibre-0.7no signal · 15%
- Ultra-processed food-0.5no signal · 15%
- Dietary fat load+0.4no signal · 15%
- Caffeine+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion
- Autonomic recovery ↑20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 3.2 · butyrate capacity 73/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 54 ms
- Sleep
- 5.9 h
- Steps
- 8,206
- Resting HR
- 59 bpm
Daily log: GI score 15, nutritional resilience 69, adherence 92.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02031 | 38% | S12 | AD-05 | improved | 47 |
| P-02285 | 36% | S14 | AD-05 | no change | 39 |
| P-02555 | 32% | S01 | AD-05 | no change | 79 |
| P-02280 | 42% | S07 | BR-03 | no change | 50 |
| P-02267 | 40% | S09 | BR-03 | no change | 45 |
| P-02638 | 38% | S01 | BR-03 | improved | 41 |
| P-02087 | 36% | S01 | BR-03 | no change | 40 |
| P-02522 | 32% | S01 | BR-03 | no change | 40 |
| P-02483 | 31% | S06 | BR-03 | no change | 64 |
| P-02218 | 38% | S01 | DT-01 | improved | 61 |
| P-02685 | 37% | S16 | DT-01 | improved | 47 |
| P-02235 | 36% | S14 | DT-01 | improved | 50 |